T h e ne w e ngl a nd jou r na l o f m e dicine A ntiplatelet therapy is an essential part of secondary prevention of cardiovascular events. 1, 2 In particular, dual antiplatelet therapy -the combination of aspirin with an oral P2Y 12 receptor antagonist -is the predominant approach in patients with acute coronary syndromes, coronary-artery stenting, or previous myocardial infarction. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] The three oral P2Y 12 receptor antagonists that are in use are clopidogrel, prasugrel, and ticagrelor.
A limitation of all three oral P2Y 12 receptor antagonists is the increased bleeding risk, which persists for several days after drug cessation. [20] [21] [22] [23] Establishment of hemostasis can be challenging in patients with major bleeding, such as intracranial or gastrointestinal hemorrhage. 24, 25 In addition, urgent invasive procedures, especially emergency procedures, are associated with an increased risk of periprocedural bleeding. If an emergency procedure is indicated, the surgeon or proceduralist must proceed while accepting the increased bleeding risk, often after empirically providing platelet transfusions, despite the ineffectiveness of such transfusions in reversing the antiplatelet effects of P2Y 12 inhibitors. If an urgent procedure is indicated, the proceduralist must either proceed while anticipating the increased bleeding risk or postpone the procedure for several days while accepting the risks associated with delaying a clinically indicated procedure. American College of Cardiology Foundation-American Heart Association, European Society of Cardiology, and other society guidelines recommend cessation of oral P2Y 12 receptor antagonists at least 3 to 7 days before surgery. 26, 27 Currently, no reversal agents for P2Y 12 receptor antagonists are known. Unlike the other P2Y 12 receptor antagonists, ticagrelor is a reversible inhibitor, which makes the development of a specific reversal agent for ticagrelor feasible. PB2452 (formerly MEDI2452) is a neutralizing monoclonal antibody fragment that binds ticagrelor and its major active circulating metabolite with high affinity. 28 We hypothesized that PB2452 could be used to reverse rapidly the antiplatelet effects of ticagrelor, thereby reducing the risk or severity of bleeding.
Me thods

Trial Design and Oversight
We conducted a single-center, randomized, doubleblind, placebo-controlled, single-ascending-dose, phase 1 trial to evaluate the safety, efficacy, and pharmacokinetic profiles of PB2452 in healthy volunteers 18 to 50 years of age who were pretreated with ticagrelor. As shown in Table S1 in the Supplementary Appendix (available with the full text of this article at NEJM.org), 10 sequential dose cohorts were evaluated. Volunteers in all cohorts were randomly assigned, in a 3:1 ratio, to receive PB2452 or placebo.
Cohorts 1, 2, and 3 each consisted of four volunteers who were randomly assigned to receive a 30-minute infusion of PB2452 at a dose of 0.1 g, 0.3 g, and 1.0 g, respectively, or placebo, in the absence of ticagrelor pretreatment, to assess the initial safety of PB2452. Volunteers in cohorts 4 through 10 were pretreated with a 180-mg loading dose of oral ticagrelor at 7 a.m. on day −2, and then with a 90-mg dose every 12 hours starting at 7 p.m. on day −2, for a total of five doses and 48 hours of pretreatment before the evaluation of PB2452. Cohorts 4, 5, and 6 each consisted of eight volunteers who were assigned to receive a 30-minute infusion of PB2452 at a dose of 1.0 g, 3.0 g, and 9.0 g, respectively, or placebo after ticagrelor pretreatment. Cohorts 7 through 10 consisted of volunteers who were assigned to receive an 18.0-g fixed dose of PB2452 according to one of four infusion regimens or placebo after ticagrelor pretreatment. In cohorts 7 through 10, PB2452 was initiated 2 hours after the administration of the last dose of ticagrelor pretreatment to coincide with the peak concentration of ticagrelor. 29 Volunteers were enrolled at Pharmaceutical Product Development, a contract clinical research organization. PhaseBio Pharmaceuticals sponsored the trial. A steering committee, which consisted of academic physicians and a representative from PhaseBio Pharmaceuticals, developed the protocol (available at NEJM.org) and was responsible for the conduct and oversight of the trial, as well as the interpretation of the data. Pharmaceutical Product Development was responsible for the collection and handling of the data. The protocol was approved by the Food and Drug Administration and a central institutional review board. All data analyses were performed by PhaseBio Pharmaceuticals. The first author wrote the first draft of the manuscript, and all the authors participated in revisions of subsequent drafts. No one who is not an author contributed to writing the manuscript. The authors vouch for the completeness and accuracy of the data and analyses and for the fidelity of the trial to the protocol. 
Outcomes
The primary efficacy outcome was reversal of the antiplatelet effects of ticagrelor as assessed by analysis of platelet aggregation with the use of light transmission aggregometry at multiple time points before and after the administration of PB2452 or placebo in volunteers who were pretreated with ticagrelor. Secondary efficacy outcomes were ticagrelor reversal as assessed with the use of a point-of-care P2Y 12 platelet-reactivity test known as the VerifyNow P2Y12 assay (Accriva) and a vasodilator-stimulated phosphoprotein (VASP) phosphorylation immunoassay known as the modified CY-QUANT VASP P2Y12 assay (BioCytex). Details regarding these assays and the interpretation of their results are provided in the Methods section of the Supplementary Appendix.
The primary safety outcome was the frequency and severity of adverse events that occurred after the initiation of PB2452 or placebo. Association of adverse events with PB2452, both in volunteers who received ticagrelor pretreatment and in those who did not, was determined by the investigator. Clinical laboratory test results, vital signs, results of 12-lead electrocardiography and continuous telemetry, and findings on physical examination were also obtained at multiple time points from screening to the end of the 28-day safety followup period. The immunogenicity of PB2452 was assessed before the administration of PB2452, as well as 7 days and 28 days afterward. Other secondary outcomes included the pharmacokinetic profiles of PB2452 and ticagrelor.
Statistical Analysis
The sample of 64 volunteers was an ad hoc decision that was based on the requirement that 4 or 8 volunteers be randomly assigned, in a 3:1 ratio, to receive either PB2452 or placebo in each dose cohort to explore adequately the safety, efficacy, and pharmacokinetic profiles of PB2452 in healthy volunteers. Reversal of the antiplatelet effects of ticagrelor was evaluated by comparing the platelet aggregation after treatment, which was expressed as a percentage of the platelet aggregation at baseline, between PB2452 and placebo with the use of the Wilcoxon rank-sum test. For efficacy data, baseline was defined as the time point immediately before the administration of ticagrelor. The Bonferroni method was used to adjust for multiple comparisons. Correlation of results between platelet-function tests was evaluated with the use of Pearson's correlation coefficient and Spearman's rank-correlation coefficient.
Mean data from volunteers who received placebo were pooled across cohorts for all analyses. Results for categorical variables are summarized with frequencies and percentages, and results for continuous variables are presented with the number of volunteers with nonmissing data, as well as means with standard deviations and medians with ranges. Descriptive statistics are presented for each cohort and for pooled placebo and PB2452 data. Platelet aggregation results were compared between each PB2452 cohort and pooled placebo data (with data for cohorts 4, 5, and 6 and data for cohorts 7 through 10 pooled separately). All analyses were performed with SAS software, version 9.4 (SAS Institute). Details regarding all statistical analyses are provided in the protocol, which includes the statistical analysis plan.
R esult s
Trial Population
From April 3, 2018, to August 23, 2018, a total of 64 volunteers underwent randomization, of whom 48 were assigned to receive PB2452 and 16 to receive placebo. Of the 48 volunteers who received PB2452, 21 received the highest dose (18 g) and 39 received ticagrelor pretreatment. Details regarding the final trial design and regarding enrollment, randomization, and follow-up are shown in Table S1 and Figure S1 , respectively, in the Supplementary Appendix. Characteristics of the volunteers at baseline are shown in Table 1 .
Safety
A total of 30 adverse events that occurred after initiation of PB2452 or placebo were reported by 19 of the 64 volunteers (30%). Of the 48 volunteers T h e ne w e ngl a nd jou r na l o f m e dicine who received PB2452, 17 (35%) reported 27 adverse events; of the 16 volunteers who received placebo, 2 (12%) reported 3 adverse events (Table 2 ). There were no dose-limiting toxic effects or infusionrelated reactions. There were no deaths or adverse events that led to discontinuation of the trial drug or hospitalization. One volunteer had 2 serious adverse events (alcohol poisoning and acute respiratory failure) 4 days after discharge from the clinical site. Except for 2 volunteers, in cohorts 1 and 3, all volunteers with adverse events had received ticagrelor pretreatment. Changes in mean clinical laboratory test results, vital signs, and electrocardiographic results were similar across cohorts among volunteers who received different doses or regimens of PB2452 and were similar among those who received PB2452 and those who received placebo.
Of the 48 volunteers who received PB2452, 21 (44%) had detectable antidrug antibodies in blood obtained 7 days, 28 days, or both after exposure; 15 (31%) had been positive before they received PB2452 and 6 (12%) became positive after they received PB2452, albeit with low titers of 40 (in 5 volunteers) and 160 (in 1 volunteer). Of the 16 volunteers who received placebo, 3 (19%) were positive for antidrug antibodies, with 2 (12%) having preexisting antibodies. All antibody titers were less than 1280, and the presence of these antibodies had no observed effect on the safety or efficacy of PB2452.
Ticagrelor Reversal
Ticagrelor reversal was assessed in cohorts 4 through 10 by analysis of platelet aggregation. Volunteers in these cohorts were pretreated with ticagrelor for 48 hours before they received PB2452 or placebo. Among volunteers who received placebo, platelet aggregation was suppressed by 80 to 85% after 48 hours of ticagrelor pretreatment and remained suppressed for an additional 24 hours after ticagrelor cessation. Platelet aggregation gradually returned closer to normal between 24 and 48 hours after the initiation of placebo (Fig. 1) . Volunteers in cohorts 5 and 6 who received a 30-minute infusion of PB2452 at a dose of 3.0 g and 9.0 g, respectively, had a significantly greater increase in platelet aggregation than those who received placebo. Maximal ticagrelor reversal occurred at 30 minutes, immediately after completion of the 30-minute infusion. The duration of reversal was dose-dependent and lasted 1 to 2 hours (Fig. 1A) .
To attain more rapid and sustained ticagrelor reversal, the total dose of PB2452 was increased to 18 g in cohorts 7 through 10 to accommodate the administration of an initial bolus and longer infusions of 8, 12, and 16 hours. In cohort 7, PB2452 was administered as a 3.0-g bolus followed by an 8-hour infusion. Although use of this regimen significantly extended the duration of reversal to * Plus-minus values are means ±SD. In general, the baseline value was defined as the last nonmissing measurement obtained before randomization. There were no significant differences between the groups with regard to baseline characteristics. † The body-mass index is the weight in kilograms divided by the square of the height in meters. ‡ Race or ethnic group was reported by the volunteer. § On light transmission aggregometry, the normal range for platelet aggregation is 72 to 94% (CirQuest Labs in-house validation). ¶ On the point-of-care P2Y 12 platelet-reactivity test (VerifyNow P2Y12 assay), the normal range for platelet reactivity units is 180 to 380 (Accriva package insert). ‖ On the vasodilator-stimulated phosphoprotein (VASP) assay (modified CY-QUANT VASP P2Y12), the normal range for the platelet reactivity index is 89 to 99% (BioCytex package insert). (Fig. 1B) . In cohorts 8, 9, and 10, PB2452 was administered as a 6.0-g bolus followed by a 12-hour or 16-hour infusion. With the larger bolus, reversal occurred within 5 minutes after initiation of the infusion and was sustained for 16 to 24 hours (Fig. 1B) . Overall, in cohorts 7 through 10, in which the PB2452 regimen was adjusted to include an initial bolus for rapid reversal and a prolonged infusion for sustained reversal, volunteers who received PB2452 (pooled) had a significantly greater increase in platelet aggregation than those who received placebo (pooled) across all time points between 5 minutes and 20 hours (P<0.001 after Bonferroni adjustment). The significant immediate and sustained ticagrelor reversal that was detected with light transmission aggregometry in the primary efficacy analysis was confirmed with the point-of-care P2Y 12 platelet-reactivity test and VASP assay ( To assess the extent to which normal platelet function was restored, in cohorts 9 and 10 (pooled), platelet function after the initiation of PB2452 was compared with platelet function at baseline (before the administration of ticagrelor) with the use of all three assays. On light transmission aggregometry, the mean platelet aggregation was restored to a normal level (≥80% of the baseline value) at all time points up to 20 hours (Fig. 2A) . On the point-of-care P2Y 12 platelet-reactivity test, the mean platelet reactivity reflected rapid and sustained normalization of platelet function, with a level of platelet reactivity units of at least 180, for 24 hours (Fig. 2B) . On assessment of P2Y 12 receptor signaling with the VASP assay, the platelet reactivity index was restored to nearly 100% of the baseline value within 5 minutes and remained at that level for 20 to 24 hours (Fig. 2C) .
To determine whether acute ticagrelor reversal causes a potentially prothrombotic rebound effect in platelet reactivity, platelet aggregation was assessed in response to a low concentration of adenosine diphosphate (5 μM, as compared with the usual 20 μM). In addition, platelet aggregation was assessed in response to other agonists, including arachidonic acid and thrombin receptor-activating peptide. As expected, the response was lower with 5 μM of adenosine diphosphate than with 20 μM (Fig. S4A and S4B in the Supplementary Appendix), and the responses to arachidonic acid and thrombin receptor-activating peptide after reversal were similar to the responses at baseline (before the administration of ticagrelor) (Fig. S4C and S4D in the Supplementary Appendix).
Pharmacokinetics
Pharmacokinetic analysis of PB2452 revealed dose-linear increases in mean exposure (maximum Ticagrelor reversal is shown as an increase in mean platelet aggregation after ticagrelor pretreatment, as assessed with the use of light transmission aggregometry. Shown are the onset and duration of ticagrelor reversal among volunteers in cohorts 4, 5, and 6, who were randomly assigned to receive either a 30-minute infusion of PB2452 at a dose of 1 g, 3 g, and 9 g, respectively, or placebo (Panel A), as well as among volunteers in cohorts 7, 8, 9, and 10, who were randomly assigned to receive an 18-g fixed dose of PB2452 with an infusion duration of 8 hours, 12 hours, 16 hours, and 16 hours, respectively, or placebo (Panel B). Mean platelet aggregation at baseline (before the administration of ticagrelor) is shown at −48 hours. P values are for the comparison of PB2452 with placebo. Statistical testing was not performed in cohort 9 because only three volunteers in that cohort received PB2452. I bars indicate the standard deviation. NA denotes not available. Antibody-Based Ticagrelor Reversal Agent T h e ne w e ngl a nd jou r na l o f m e dicine
Among volunteers who received 18 g of PB2452 with longer infusions and ticagrelor pretreatment, PB2452 exposure was maintained for 12 to 24 hours, and the mean AUC 0-48 hours for ticagrelor was increased by a factor of 5.6. The increased ticagrelor exposure probably reflected tight binding between PB2452 and ticagrelor and redistribution of extravascular ticagrelor into the vascular compartment. Details regarding the pharmacokinetic profiles of PB2452 and ticagrelor are provided in Figure S5A through S5D in the Supplementary Appendix.
Discussion
In this trial, intravenous infusion of the monoclonal antibody fragment PB2452 significantly reversed the antiplatelet effects of ticagrelor, as measured by multiple assays of platelet function.
In the healthy trial population, there were no serious adverse events or infusion-related reactions that were determined to be associated with PB2452. It remains unclear whether reversal of the antiplatelet effects of ticagrelor by PB2452 would lead to more rapid hemostasis in patients with bleeding or to prevention of bleeding in patients who are undergoing urgent invasive procedures. The ability to reverse the action of novel oral anticoagulants has been a major advance in antithrombotic therapy. 30, 31 Currently, no effective methods for reversal of the antiplatelet effects of oral P2Y 12 antagonists, such as ticagrelor, are available other than stopping the drug and waiting 3 to 5 days for its effects to dissipate, a method that is problematic in patients who have lifethreatening bleeding or a high risk of thrombosis. Treatment guidelines and prescription information for P2Y 12 inhibitors recommend drug cessation 3 to 7 days before surgical procedures. Waiting this long is impossible in patients who are undergoing emergency surgery and may be inadvisable for those who are undergoing urgent surgery. Platelet transfusion may be considered for attempting reversal of aspirin and some P2Y 12 receptor antagonists but is not useful in patients who are receiving ticagrelor, because the free drug binds to fresh platelets. 32, 33 Therefore, a ticagrelor reversal agent would be useful.
PB2452 is a recombinant human IgG1 monoclonal antibody antigen-binding fragment that binds with high affinity and specificity to rapidly neutralize ticagrelor and its active metabolite AR-C124910XX. 28 The high affinity and specificity of PB2452 enables it to neutralize free ticagrelor and prevent binding to the P2Y 12 receptor. These properties explain the immediate reversal that was observed with PB2452, and such reversal is a key feature for patients with hemorrhage. The mechanism of action is expected to be specific to ticagrelor and not work with clopidogrel or prasugrel, which are irreversible P2Y 12 receptor antagonists.
There are some limitations of this trial. The trial involved healthy volunteers and not patients with atherosclerosis. The sample size was small. Because the trial involved healthy volunteers and not patients with bleeding who were already taking ticagrelor, the results may not be predictive of the reversal or safety profile of PB2452 in that patient population or the effect of PB2452 on the establishment of hemostasis or the prevention of bleeding.
Several clinical studies that have used the same assays have correlated platelet inhibition with bleeding risk. [34] [35] [36] In a literature review and expert consensus statement and in a large meta-analysis of 17 clinical trials that included more than 20,000 patients who were undergoing percutaneous coronary intervention and whose platelet function was measured with the use of a point-of-care P2Y 12 platelet-reactivity test or a VASP assay, low platelet reactivity was independently associated with an elevated bleeding risk. 37, 38 In this trial involving volunteers who were pretreated with ticagrelor, low platelet reactivity was rapidly reversed by a new targeted monoclonal antibody fragment.
In conclusion, we found that the administration of intravenous PB2452 reversed the antiplatelet effects of ticagrelor, as measured by multiple assays of platelet function, and was associated with minimal low-grade toxic effects.
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